CHLORPROMAZINE

Comments:

Chlorpromazine produces behavioural changes and blocks many cell membrane receptors, notably those for dopamine and norpinephrine. Besides its tranquillizing and sedative actions, it shows synergism with other classes of central nervous system depressants. Studies indicate possible concerns for genotoxicity, adverse effects on reproduction, and developmental neurotoxicity. Therapeutic doses in humans may cause adverse effects on the circulatory and nervous systems, blood cells, the skin, and the eye. Interference with human pituitary and gonadal function results in galactorrhoea and amenorrhoea. In view of the lack of relevant toxicological data, the long-term persistence of chlorpromazine in humans, the spectrum of additional effects of the drug, and the probability that even small doses can cause behavioural change, the Committee was unable to establish an ADI. Furthermore the Committee suggested that chlorpromazine should not be used in food producing animals.

MRL Comment:

No MRLs allocated

MRL Code:

O

Meeting:

38

Report: 

Tox Monograph: 

Residues: